Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer
Preethi Krishnan(Indiana University School of Medicine), Sambasivarao Damaraju(University of Alberta), John R. Mackey(University of Alberta), Richard Berendt(College of the Holy Cross), Ashok Narasimhan(Indiana University School of Medicine), Sunita Ghosh(Tata Memorial Hospital), Kathryn Graham(Alberta Health Services), Bo Wang, Dongping Li(University of Lethbridge), Olga Kovalchuk(University of Lethbridge)
Cited by 78
Related Papers
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
|Journal of Clinical Oncology|2009|850
Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer
|British Journal of Cancer|2008|651
Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin
|Molecular Cancer Therapeutics|2008|635